# ARA-290 Peptide

> ARA-290 is an erythropoietin-derived peptide that activates tissue-protective repair signaling without stimulating red blood cell production.

Canonical: https://pepflow.app/peptides/ara-290/

The Nerve Protector

An 11-amino-acid erythropoietin-derived peptide engineered to activate tissue-protective innate repair signaling without stimulating red blood cell production.

Nerve repair  Inflammation  Tissue protection

Tier C

Evidence Preliminary

Safety Moderate Data

FDA status Not Approved

Last reviewed August 11, 2026 12 citations [How to read these labels](<https://pepflow.app/peptide-label-legend/>)

## What is ARA-290?

ARA-290, also called cibinetide, is modeled from the helix B surface of erythropoietin. It was designed to keep EPO-like tissue-protective signaling while avoiding classical erythropoietic stimulation of red blood cell production.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/29392190/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/25387363/>)

The strongest human signal is in small fiber neuropathy, especially sarcoidosis-associated neuropathic symptoms and corneal nerve fiber measures. These studies are small, but they are more clinically developed than most research-market peptides.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/23168581/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24555851/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28475703/>)

ARA-290, cibinetide, and helix B surface peptide are closely related naming lanes for the same EPO-derived tissue-protective peptide concept. The naming should not be confused with erythropoietin itself, because ARA-290 was engineered around nonerythropoietic repair signaling rather than red-blood-cell stimulation.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/25387363/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/29392190/>)

## What ARA-290 is investigated for

ARA-290 evidence is grouped by practical use case and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

### ### Sarcoidosis-associated small fiber neuropathy Injectable 55% Emerging

Sarcoidosis-associated small fiber neuropathy is the strongest ARA-290 human signal, but larger confirmatory trials are still needed.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/23168581/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24555851/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28475703/>)

#### Human evidence

Small randomized and follow-up studies support symptom and function signals in sarcoidosis-associated small fiber neuropathy.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/23168581/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24555851/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28475703/>)

#### Animal / mechanistic evidence

Mechanistic support centers on tissue-protective innate repair signaling rather than erythropoiesis.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/23168581/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24555851/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28475703/>)

### ### Corneal nerve regeneration Injectable 52% Emerging

Corneal nerve findings strengthen the neuropathy story, but durable visual or sensory outcome benefit still needs confirmation.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28475703/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/29392190/>)

#### Human evidence

A sarcoidosis-associated small fiber neuropathy study reported improved corneal nerve fiber abundance measured by confocal microscopy.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28475703/>) [\[10\]](<https://clinicaltrials.gov/study/NCT02039687>)

#### Animal / mechanistic evidence

The same innate repair receptor biology supports nerve-fiber protection and regeneration hypotheses.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/29392190/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28475703/>)

### ### Diabetic neuropathy and metabolic control Injectable 50% Emerging

Diabetic neuropathy and metabolic-control findings are promising but less established than the sarcoidosis neuropathy signal.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/25387363/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/29392190/>)

#### Human evidence

A Phase 2 study reported neuropathic-symptom and metabolic-control findings in type 2 diabetes, but replication is needed.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/25387363/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/29392190/>)

#### Animal / mechanistic evidence

The tissue-protective mechanism is plausible in metabolic and inflammatory injury contexts.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/25387363/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/29392190/>)

### ### Tissue-protective signaling Injectable 44% Preliminary

The innate-repair mechanism supports research interest across injury models, but broad tissue-repair treatment claims are not established.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/29392190/>)

#### Human evidence

Human tissue-repair outcomes outside neuropathy are not established.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/29392190/>)

#### Animal / mechanistic evidence

The innate repair receptor model supports anti-inflammatory and cell-survival signaling.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/29392190/>)

### ### Chronic pain and neuroinflammation Injectable 38% Preliminary

Chronic-pain positioning should stay tied to neuropathy and neuroinflammation research rather than generalized analgesic claims.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/23168581/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/29392190/>)

#### Human evidence

Pain-related human findings come from small neuropathy studies, not broad chronic-pain trials.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/23168581/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/25387363/>)

#### Animal / mechanistic evidence

Review literature places ARA-290 in tissue-protective and anti-inflammatory signaling relevant to neuropathy and neuroinflammation models.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/29392190/>)

## Evidence snapshot

### Overall confidence

Emerging

58%

ARA-290 has meaningful early human neuropathy evidence and a coherent tissue-protective rationale. Sample size, endpoint scope, and missing Phase 3 confirmation keep confidence in the emerging range.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/23168581/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28475703/>)

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

55%

### Human evidence

Emerging

Small Phase 2 and randomized studies support sarcoidosis-related small-fiber neuropathy and type 2 diabetes neuropathic-symptom signals. The evidence is still narrow.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/23168581/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/25387363/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28475703/>)

48%

### Animal / preclinical

Preliminary

Preclinical tissue-protective studies support the innate-repair rationale behind the human neuropathy work. They should not be generalized into broad tissue-repair claims.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/29392190/>)

65%

### Mechanism support

Moderate

The engineered EPO helix B design and innate-repair-receptor concept give ARA-290 a clear mechanism. It is designed to avoid erythropoietic signaling.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/29392190/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/25387363/>)

## Forms & administration

ARA-290 administration is mainly an injectable clinical-research context. Neuropathy-oriented protocols commonly use a short daily course.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/23168581/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/25387363/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28475703/>)

Injectable

## Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

### Typical Range

Common injectable protocols use 2-4 mg per dose.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/23168581/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28475703/>)

### Frequency

Usually taken once daily.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/23168581/>)

### Timing Considerations

Take at a consistent time, usually morning or evening.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/23168581/>)

### Cycle Length

Common cycles run 4-8 weeks.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/23168581/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28475703/>)

[Full ARA-290 dosage guide](<https://pepflow.app/peptides/ara-290/dosage/>)

## What to expect

### Weeks 1-4

Injectable neuropathy-oriented use may first show changes in burning pain, numbness, sleep disruption, or day-to-day function.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/23168581/>)

### Weeks 4-8

Pain, function, and sensory symptoms are easier to compare against baseline over a full daily course; objective nerve-fiber changes require clinical testing.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28475703/>)

### After stopping

Pain relief, function, and sensory comfort may hold or fade after the daily course ends.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24555851/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28475703/>)

## Safety profile

Injectable ARA-290 safety centers on local tolerability, repeated-course exposure, pregnancy avoidance, oncology context, and whether its nonerythropoietic design holds across chronic use. Small studies provide human tolerability context, but not a mature long-term safety profile.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/23168581/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/25387363/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28475703/>)

### Common side effects

- Injection-site pain or swelling [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/23168581/>)

### Cautions

- EPO-pathway context[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/25387363/>)
- Oncology context[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/29392190/>)

### What we don't know

Durable safety and response after repeated or chronic courses are not established.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24555851/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28475703/>)

## Who ARA-290 is not for

Route-specific avoid and medical-review notes:

- **Pregnancy or breastfeeding**

  Avoid because reproductive safety has not been established.[\[6\]](<https://api.fda.gov/drug/drugsfda.json?search=%22ARA-290%22&limit=1>)
- **Active cancer or proliferative disease**

  Medical review is warranted because tissue-protective signaling and growth-factor-adjacent contexts need disease-specific judgment.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/29392190/>)

## Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

### Theoretical interactions

- **EPO or erythropoiesis-stimulating therapies**

  EPO or erythropoiesis-stimulating therapy overlaps with ARA-290's EPO-derived biology; the interaction concern is theoretical because ARA-290 was designed to avoid red-cell stimulation.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/25387363/>)

## Regulatory status

### United States

ARA-290/cibinetide has no FDA-approved injectable human use as of 2026-06-21. Research, orphan-style development history, or compounded availability does not create FDA review of safety, effectiveness, quality, or market authorization.[\[6\]](<https://api.fda.gov/drug/drugsfda.json?search=%22ARA-290%22&limit=1>) [\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Cibinetide%22&limit=1>) [\[9\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)

| Route | FDA drug approval | 503A compounding |
| --- | --- | --- |
| Injectable | Not Approved · As of 2026-06-21, ARA-290/cibinetide was not FDA-approved as an injectable drug. Clinical-trial activity does not create U.S. market authorization.[\[6\]](<https://api.fda.gov/drug/drugsfda.json?search=%22ARA-290%22&limit=1>) [\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Cibinetide%22&limit=1>) | Not Listed · As of 2026-06-21, ARA-290/cibinetide was not identified on FDA's reviewed 503A bulk-substance materials for injectable compounding. Compounded preparations are still not FDA-approved drugs.[\[8\]](<https://www.fda.gov/media/94155/download>) [\[9\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) |

### Injectable

FDA drug approval

Not Approved

As of 2026-06-21, ARA-290/cibinetide was not FDA-approved as an injectable drug. Clinical-trial activity does not create U.S. market authorization.[\[6\]](<https://api.fda.gov/drug/drugsfda.json?search=%22ARA-290%22&limit=1>) [\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Cibinetide%22&limit=1>)

503A compounding

Not Listed

As of 2026-06-21, ARA-290/cibinetide was not identified on FDA's reviewed 503A bulk-substance materials for injectable compounding. Compounded preparations are still not FDA-approved drugs.[\[8\]](<https://www.fda.gov/media/94155/download>) [\[9\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)

### International

EU/Europe, UK, Canada, and Australia should be checked by local product and claim; trial activity and orphan-style development history should not be read as market approval.

### Sports & competition

WADA's 2026 Prohibited List does not specifically name ARA-290, but tested athletes should treat systemic use of a non-approved pharmacological substance as an S0 risk unless cleared through anti-doping review.[\[12\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)

## How it works

ARA-290/cibinetide is engineered from erythropoietin biology but is meant to avoid classical red-blood-cell stimulation. Its proposed target is innate repair receptor signaling, a tissue-protective pathway discussed around cell-protection, nerve injury, inflammation, and metabolic stress.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/25387363/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/29392190/>)

That mechanism fits sarcoidosis-associated small fiber neuropathy and corneal nerve-fiber endpoints better than broad pain or longevity claims. The injectable route gives systemic exposure, so the key question is whether receptor-level repair signaling produces durable symptom and nerve-fiber improvements in larger, longer trials in treated patients.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/23168581/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28475703/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/29392190/>)

## Research gaps & open questions

What the current literature has not yet settled about ARA-290:

01

Larger late-stage trials still need to confirm whether ARA-290 meaningfully improves pain, daily function, and nerve-fiber health in people with neuropathy.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/23168581/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28475703/>)

02

Studies have not established how long treatment should continue, whether benefits last after stopping, or how safe repeated courses are.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24555851/>)

03

Results in sarcoidosis and diabetic neuropathy cannot answer whether ARA-290 works for other conditions; each condition needs its own trials.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/25387363/>)

## Common questions

### How is ARA-290 different from EPO?

ARA-290 comes from EPO biology but is engineered for tissue-protective signaling without intended red-blood-cell stimulation.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/25387363/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/29392190/>)

### What is the best-supported ARA-290 use case?

Sarcoidosis-associated small fiber neuropathy has the most direct human support, including injectable small-study data on symptoms and corneal nerve fibers.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/23168581/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28475703/>)

### Is ARA-290 FDA-approved?

No. ARA-290/cibinetide has no FDA-approved injectable human use as of 2026-06-21; clinical-trial activity does not create market authorization.[\[6\]](<https://api.fda.gov/drug/drugsfda.json?search=%22ARA-290%22&limit=1>) [\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Cibinetide%22&limit=1>) [\[9\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)

## Myths & misconceptions

### Myth

ARA-290 raises red blood cells like EPO.

### Reality

It was engineered to retain tissue-protective signaling without classical erythropoietic activity.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/25387363/>)

### Myth

Phase 2 neuropathy data means ARA-290 is an approved neuropathy drug.

### Reality

Small Phase 2 studies are promising but do not replace Phase 3 confirmation or regulatory approval.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/23168581/>) [\[6\]](<https://api.fda.gov/drug/drugsfda.json?search=%22ARA-290%22&limit=1>)

## History & discovery

ARA-290, later known as cibinetide, grew out of attempts to preserve erythropoietin's tissue-protective signaling while avoiding the red-blood-cell stimulation that makes EPO clinically complicated.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/29392190/>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/23168581/>)

A randomized pilot study tested ARA-290 in sarcoidosis-associated small fiber neuropathy, moving the peptide from innate-repair biology into human symptom research.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/23168581/>)

A type 2 diabetes study extended the tissue-protection idea to metabolic control and neuropathic symptoms, still in a small clinical setting.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/25387363/>)

Later sarcoidosis work used corneal nerve fiber abundance as an endpoint, creating a measurable but still limited human evidence thread.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28475703/>)

## Published research 12 citations

- [\[1\] **Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.** Molecular medicine (Cambridge, Mass.), 2012 Nov 15. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/23168581/>)
- [\[2\] **ARA 290 for treatment of small fiber neuropathy in sarcoidosis.** Expert opinion on investigational drugs, 2014 Apr. review.](<https://pubmed.ncbi.nlm.nih.gov/24555851/>)
- [\[3\] **ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.** Molecular medicine (Cambridge, Mass.), 2015 Mar 13. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/25387363/>)
- [\[4\] **Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain.** Investigative ophthalmology & visual science, 2017 May 1. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/28475703/>)
- [\[5\] **Targeting the innate repair receptor to treat neuropathy.** Pain reports, 2016 Jul. review.](<https://pubmed.ncbi.nlm.nih.gov/29392190/>)
- [\[6\] **Drugs@FDA/openFDA query for ARA-290** U.S. Food and Drug Administration / openFDA. database query.](<https://api.fda.gov/drug/drugsfda.json?search=%22ARA-290%22&limit=1>)
- [\[7\] **Drugs@FDA/openFDA query for Cibinetide** U.S. Food and Drug Administration / openFDA. database query.](<https://api.fda.gov/drug/drugsfda.json?search=%22Cibinetide%22&limit=1>)
- [\[8\] **Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act** U.S. Food and Drug Administration, 2026-05-14. regulatory.](<https://www.fda.gov/media/94155/download>)
- [\[9\] **Compounding and the FDA: Questions and Answers** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)
- [\[10\] **Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis** ClinicalTrials.gov. clinical trial registry.](<https://clinicaltrials.gov/study/NCT02039687>)
- [\[11\] **ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)** ClinicalTrials.gov. clinical trial registry.](<https://clinicaltrials.gov/study/NCT01933529>)
- [\[12\] **The 2026 List of Prohibited Substances and Methods** World Anti-Doping Agency, 2026. regulatory.](<https://ita.sport/resource/wada-2026-prohibited-list/>)

[PepFlow library coverage](<https://pepflow.app/research/peptide-library/>)

## Quick facts

**Family**

Endogenous fragment peptide

**Tier**

C

**Evidence**

58% Preliminary

**Safety**

Moderate Data

**FDA status**

Not Approved

**Injectable 503A**

Not Listed

**Citations**

[12 citations](<https://pepflow.app/peptides/ara-290/#published-research>)

**Updated**

August 11, 2026

### Potential benefits

- Sarcoidosis-associated small fiber neuropathy
- Corneal nerve regeneration
- Diabetic neuropathy and metabolic control
- Tissue-protective signaling
- Chronic pain and neuroinflammation

### Common side effects

- Injection-site pain or swelling

### Also known as

- ARA-290
- Cibinetide
- Helix B surface peptide
- HBSP

## Related

- [Peptide Label Key](<https://pepflow.app/peptide-label-legend/>)
- [ARA-290 dosage guide](<https://pepflow.app/peptides/ara-290/dosage/>)
- [PepFlow Library Statistics (2026) · 65 Profiles](<https://pepflow.app/research/peptide-library/>)
